



## **BioCryst to Present New Data for BCX4208 Monotherapy at the 74th Annual American College of Rheumatology (ACR) Scientific Meeting**

- ***BioCryst to Host Conference Call & Web cast Today at 6:30 p.m. Eastern Time***

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced the presentation of new data related to the efficacy and safety of BCX4208 for the treatment of gout at the 74<sup>th</sup> ACR Scientific Meeting being held in Atlanta, Georgia.

The data will be presented during a poster session scheduled for today, November 8, 2010 from 9:00-11:00 a.m. Eastern Time. The poster to be presented during the session is entitled:

- "Effects of a Purine Nucleoside Phosphorylase Inhibitor, BCX4208, on the Serum Uric Acid Concentrations in Patients with Gout". This poster concludes that BCX4208 doses administered at 40, 80, 120, 160 and 240 mg once-daily monotherapy rapidly and significantly reduced serum uric acid (sUA) in patients with gout. BCX4208 was generally safe and well-tolerated at the doses evaluated in this study.

### **Conference Call and Web Cast**

BioCryst will host a conference call and Web cast today at 6:30 p.m. Eastern Time where a summary of the new BCX4208 data presented at ACR will be reviewed by Dr. William Sheridan, Chief Medical Officer at BioCryst, and commentary regarding gout prevalence and patient demographics as well as current and emerging treatment options will be provided by Dr. Robert Terkeltaub, VA Rheumatology Section Chief, San Diego Professor of Medicine.

To participate in the conference call, please dial 1-877-303-8027 (United States) or 1-760-536-5165 (International). No passcode is needed for the call. The Web cast can be accessed by logging onto <http://www.biocryst.com>. Please connect to the Web site at least 15 minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary.

### **About BCX4208**

BCX4208 is a next generation purine nucleoside phosphorylase (PNP) inhibitor with the potential for once-a-day dosing suitable for chronic administration. With its unique mechanism of action, clinical activity and safety in clinical studies to date as well as its potential synergy with approved therapies, BCX4208 has the potential to address unmet medical needs across a broad spectrum of inflammatory and autoimmune diseases. In September 2010, BioCryst reported positive results from its Phase 2 study of BCX4208 alone and in combination with allopurinol in patients with gout, announcing that the study met its primary endpoint related to serum uric acid (sUA) reduction, demonstrated a dose-response for both BCX4208 and allopurinol, and that the combination of BCX4208 and allopurinol was shown to be superior to either drug alone in sUA reduction. For more information about BCX4208 please visit BioCryst's Web site at [http://www.biocryst.com/bcx\\_4208](http://www.biocryst.com/bcx_4208).

### **About BioCryst**

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, inflammatory diseases and cancer. BioCryst currently has three novel late-stage compounds in development: peramivir, a neuraminidase inhibitor for the treatment of influenza, BCX4208, a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout, and forodesine, an orally-available PNP inhibitor for hematological malignancies. Utilizing crystallography and structure-based drug design, BioCryst continues to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. For more information, please visit the Company's Web site at [www.biocryst.com](http://www.biocryst.com).

### **Forward-Looking Statements**

This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future

events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: that ongoing and future pre-clinical and clinical development of BCX4208 may not have positive results; that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed; that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates; that our product candidates may not receive required regulatory clearances from the FDA; that ongoing and future pre-clinical and clinical development may not have positive results; that we or our licensees may not be able to continue future development of our current and future development programs; that our development programs may never result in future product, license or royalty payments being received by BioCryst; that BioCryst may not be able to retain its current pharmaceutical and biotechnology partners for further development of its product candidates or it may not reach favorable agreements with potential pharmaceutical and biotechnology partners for further development of its product candidates; that our actual cash burn rate may not be consistent with our expectations; that BioCryst may not have sufficient cash to continue funding the development, manufacturing, marketing or distribution of its products and that additional funding, if necessary, may not be available at all or on terms acceptable to BioCryst. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and current reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially from those contained in our projections and forward-looking statements.

BCRXW

BioCryst Pharmaceuticals

Investors:

Robert Bennett, +1-919-859-7910

or

WCG

Media:

Catherine Collier Kyroulis, +1-212-301-7174

Source: BioCryst Pharmaceuticals, Inc.

News Provided by Acquire Media